Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice

José Ramón Santos, José Moltó, Josep Maria Llibre, Nuria Pérez, Mari Carmen Capitán, Cristina Miranda, Bonaventura Clotet

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

Objective: To assess the effectiveness and safety of antiretroviral therapy with unboosted atazanavir (400 mg once daily) plus co-formulated abacavir/lamivudine as a treatment simplification strategy in HIV-infected patients with sustained viral suppression in routine clinical practice. Methods: We performed a retrospective study including patients who were switched to unboosted atazanavir plus abacavir/lamivudine and whose HIV-1 RNA was <50 copies/mL. The primary endpoint was the percentage of subjects who maintained viral suppression after 48 weeks of follow-up. Secondary endpoints included the percentage of subjects who maintained viral suppression after 96 weeks of follow-up, the incidence of adverse events, changes in CD4+ T-cell count and in lipid profile, and the percentage of patients with subtherapeutic atazanavir trough concentrations during follow-up. Results: Forty-six patients were included. None had a prior history of resistance to protease inhibitors or to lamivudine or abacavir. The percentage of patients with viral suppression at Week 48 was 73.9% when all the included patients were considered (full dataset analysis) and 85.0% when only subjects on treatment were considered. There was a continuous immune recovery and an improvement in lipid profile during follow-up. Two thirds of the patients had subtherapeutic atazanavir trough concentrations in plasma in at least one determination during follow-up. Conclusion: Antiretroviral therapy with unboosted atazanavir plus abacavir/lamivudine is safe and effective in the long term as a treatment simplification strategy in HIV-infected patients with sustained virological suppression in routine clinical practice. © 2009 Thomas Land Publishers, Inc.
Original languageEnglish
Pages (from-to)129-134
JournalHIV Clinical Trials
Volume10
Issue number3
DOIs
Publication statusPublished - 1 Jan 2009

Keywords

  • Lamivudive/abacavir co-formulated
  • Simplification strategy
  • Unboosted ATV

Fingerprint Dive into the research topics of 'Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice'. Together they form a unique fingerprint.

  • Cite this